NEWS COMMENTARY

U.S. FDA approves first Chinese cancer drug for use in American patients

Published:
November 18, 2019
Services:
CPG More...
Priorities:
“Better-for-You” Transformation More...
Activities:
Markets More...
Average importance

The accelerated approval is ahead of even China's own national drug regulator. The drug is a treatment for mantle cell lymphoma (MCL) in adult patients who have received at least one prior therapy and is the first in a raft of cancer drugs the FDA is readying for regulatory approval. In a vote of confidence in its pipeline, American generics giant Amgen, bought a 20.5% stake in BeiGene earlier this month for $2.7 billion to jointly develop cancer therapies. We expect more and more innovative and promising Chinese biotech companies to expand outside their own domestic markets, and clients should leverage this growing shift in strategy and find suitable entry points for partnership opportunities to benefit from this expansion.

For the original news article, click here .


Further Reading

Singaporean precision medicine startup Hummingbird Bioscience nets $125 million in Series C funding led by Novo Holdings

News Commentary | May 24, 2021

This will further expand Hummingbird's proprietary Rational Antibody Discovery (RAD) platform for novel therapeutic monoclonal antibodies. The market for therapeutic antibodies is rapidly growing, as new drugs have been approved for treating various human diseases, including many cancers and ... Not part of subscription

Pfizer will acquire Trillium Therapeutics for $2.26 billion, seeking to further boost its capabilities in oncology

News Commentary | August 27, 2021

Trillium is a developer of a novel immunotherapy solution that targets a molecule called CD47 on cancer cells. In healthy cells, CD47 plays a part in displaying a "don't‑eat‑me" signal to the immune system. Malignant cancer cells display these molecules on their surface to evade the immune system. ... Not part of subscription

Genevant enters partnership with Takeda for developing rare liver disease therapies

News Commentary | September 08, 2021

Genevant Sciences develops lipid nanoparticle (LNP) nucleic acid delivery techniques, which can be utilized for mRNA‑based applications including vaccines, protein production, and nonviral gene therapies. The two companies reached an agreement for Genevant to develop therapeutics for two undisclosed... Not part of subscription